Roche Finally Gets Nod With Sweetened $3.4 Billion Bid For Ventana
This article was originally published in The Gray Sheet
After seven months and a half-dozen attempts at acquiring tissue-based cancer test maker Ventana Medical Systems, Roche finally won over the firm's board with a sweetened bid worth $3.4 billion
You may also be interested in...
With current technology and resources, a well-funded in vitro diagnostics company can create and pursue a strategy of information gathering and informatics application to create medical knowledge, enabling it to assume the risk and manage certain segments of patients. But few if any pharma or diagnostics firms appear poised to take advantage.
New CEOs at Vapotherm, Accelr8 and DiaGenic ASA.
With $5.7 billion hostile takeover attempt for next-generation gene sequencing powerhouse Illumina, Roche says it is uniquely situated to push sequencing into the routine clinical diagnostics space. But Illumina is resisting, which could push up the price and draw out the process.